anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject cosmetic capable of making powder exist in the vicinity of the surface of a substrate, efficiently transferring the powder to the skin after cleaning and providing a comfortable feeling, useful for cleaning of body, shaving, etc. by supporting the powder composed of a synthetic polymer substance, etc., and an aqueous medium on the sheetlike substrate. SOLUTION: This sheetlike cosmetic is obtained by supporting (A) one or more powders (preferably an organic silicone group-containing polymer) composed of a synthetic polymer substance or a natural mineral and (B) an aqueous medium such as water or the like on (C) a sheetlike (e.g. cotton sheet or the like). The cosmetic can be prepared by a method for dispersing the component A into the component B and spraying or applying the dispersion to the component C. Preferably the component A comprises &gt;=60 wt.% based on the total powders of a powder having 0.5-30 μm particle diameters. In the cosmetic, preferably 0.5-10 g of the powder having 0.5-30 μm particle diameter in the component A is contained in 1 square meter of the component C.
PURPOSE:To provide an antibacterial agent having extremely strong antibacterial effect on bacteria, especially indigenous pathogenic bacteria on the skin and cariogenic bacteria, free from toxicity and stimulation and useful for the maintenance of the health of human and animal. CONSTITUTION:An acid-hydrolyzed lactoferrin free from iron-bonding activity is used as an active component of the objective antibacterial agent. An agent such as solution, powder, sol, gel, emulsion or wax containing &gt;=0.001wt.% (preferably 0.01-0.1wt.%) of the acid-hydrolyzed lactoferrin is applied to the skin by coating, rubbing or spraying (in the form of aerosol). Any kind of lactoferrin of arbitrary origin may be used as a material for the acid-hydrolyzed product. For example, lactoferrin produced by tissue culture, chemical synthesis or gene recombination can be used for the purpose. The hydrolyzed product is produced by partially hydrolyzing the lactoferrin with an acid at 80-100 deg.C for an extremely short time to an extent to eliminate the iron-bonding capability.
PURPOSE:To exactly and properly control stock without stopping on-line processing in a stock control system for medicines in a hospital or the like by preparing a stock remaining quantity as of the end of the last month and a present stock quantity on a master record, correcting the remaining stock quantity as of the last month with the actual stock quantity as of the end of the last month, and compensating the present stock quantity with the corrected stock quantity. CONSTITUTION:A remaining stock quantity as of the last month 11 and a present stock quantity 12 are prepared on a stock master record 1. This present stock quantity 12 is set to the same quantity as the remaining stock quantity as of the end of the last month as a initial value when a system is constructed. And, an on-line renewal (a) such as for stock, delivery, etc., from a terminal 2 is made only to the present stock quantity 12. And, the stock quantity at the end of the last month x 11 is amended (b) by stocktaking data obtained at the end of month. Next, x&#39;-x is obtained as a compensation value for compensating the present stock quantity y 12, and the theoretical stock quantity y&#39; at present can be obtained. By this constitution, the stock control without stopping on-line processing is made possible.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for therapy for B-cell malignancy.  &lt;P&gt;SOLUTION: The method for therapy for B-cell malignancy is provided. The method comprises a process for administration of a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cells. Antagonist activity of the anti-C antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention relates to a Chinese patent medicine, namely Weibingzhi, which is used for treating various kinds of refractory gastrophy. The cause of gastropathy represents that the intimae of the stomach is infected to generate pathogenic bacteria such as helicobacter pylori, etc. which penetrate in the gastric mucosa to combine with gastric protein to form proteinase, and the proteinase decomposes the gastric protein to secrete harmful substances such as gastric acid, etc. The root cause of gastropathy represents that the intimae of the stomach is injured to form diseases such as carbuncle, ulcers, gastritis, antral gastritis, etc. The weakness of gastropathy represents that disease symptoms of descended extreme hypofunction of the stomach, lowered gastric motility, gastroptosis, etc. occur because of pathological changes. The manifestation of gastropathy represents that depressed vital energy and dyspeptic diseases which are caused by exopathic cause of wind-cold-wetness evil, hungriness, distension, heat, cold, etc. according to an inventor&#39;s research, and various kinds of refractory gastropathy are caused by manifestation cause, root cause and actual cause. In conclusion, the Chinese patent medicine has a reasonable and accurate medicine recipe and very strong symptomatic pertinency.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a stick cosmetic having excellent falling strength, break-off strength in use and usability.  &lt;P&gt;SOLUTION: The stick cosmetic comprises 5-50 mass % based on the total amount of the stick cosmetic of extender pigment having 0.05-0.5 μm thickness and 20-200 aspect ratio. The stick cosmetic is preferably a core for a pencil-shaped cosmetic. The extender pigment is preferably synthetic phlogopite and/or boron nitride. The stick cosmetic is mixed with 10-60 mass % based on the total amount of the stick cosmetic of a solid oil component.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gel-like substance which can be used as a moisturizing agent, is applied on the skin to prevent the dryness of the skin, has good touch, when directly applied on the skin, and smoothens the surface of the skin, when applied on the skin.  &lt;P&gt;SOLUTION: This gel-like substance is characterized by making a moisture-retaining polymer (water-absorbing polymer) powder having a particle diameter of 20 to 50μm to absorb 50 to 200-fold wt. amount of water to form the gel. The method for producing the gel-like substance is characterized by adding water to the powder of a moisture-retaining polymer and simultaneously stirring the mixture at a high rotation rate to make the polymer to absorb 50 to 200-fold wt. amount of the water.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a high-precision tailor-made medicine prescription system for prescribing medicine in terms of selection, dosage and dose regimen according to the genetic information of a patient without causing a problem of the violation of privacy.  &lt;P&gt;SOLUTION: A personal gene integrating database 102 stores personal gene information while associating it with a patient ID. A gene analysis information register means 113 of a gene analysis institution terminal 30 registers the personal gene information analyzed by a gene analysis institution to the personal gene integrate database 102. A medical institution terminal 10 conducts settlement process for paying the registration cost of the personal gene information from the patient to the gene analysis institution and confirms the will of the patient whether the view of the gene information is permitted or not. The medical institution terminal 10 accesses the personal gene integrating database 102 via the Internet 100 in the case that the will of view permission is confirmed and conducts the search of the gene information by using the patient ID of the patient and displays the searched gene information for a doctor in charge.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain a solid cosmetic having no excessive whitening, a good feeling in use and excellently deodorizing effects, comprising collapsed porous silica beads containing a fixed amount of fine particles of deodorizing metallic compound having specific particle diameters and no large voids. CONSTITUTION:An aqueous solution of alkali metal silicate having dispersed fine particles of deodorizing metallic compound (e.g. magnesium oxide or aluminum oxide) having 0.001-0.3mum diameter of primary particle is emulsified in an organic solvent in the presence of an emulsifying agent to prepare a water- in-oil type emulsion, which is mixed with an aqueous solution of a compound showing an insoluble silica forming reaction with an alkali metal silicate to give collapsed porous silica beads not substantially containing voids having &gt;=0.3mum in the particles. These beads are used to give a solid cosmetic. SiO2 content of the aqueous solution of alkali metal silicate is &gt;=5.0mol/l. The cosmetic is preferably blended with a bond auxiliary such as bees wax, nylon or lanolin and an active ingredient suppressive sweating such as aluminum chloride or zinc sulfate.
Several hemostatic bandages that are commercially available function by tightly sealing a wound so that hemostasis can occur before excessive blood loss takes place. Hemostatic bandages which seal a wound but which do not actually speed the coagulation mechanism include chitosan and chitin-based bandages. Hemostatic gauzes based on chemically modified cellulose are also commercially available. These bandages and gauzes, used in combination with various inorganic materials such as zeolite, silica, and/or diatomaceous earth powder show a synergistic effect. It has been found that the inorganic material activates the contact coagulation mechanism while the biopolymer component binds the wound and prevents excessive blood loss. ® KIPO &amp; WIPO 2009
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gene transfer agent in which adsorption of serum protein is inhibited.  &lt;P&gt;SOLUTION: The gene transfer agent has a branch type polymer containing an aromatic ring as a nuclei and having a plurality of cationic branched chains extending radially therefrom and the gene transfer agent is composed of a crosslinked polymer in which a plurality of the cationic branched polymers are crosslinked to each other through a nonionic crosslinked chain. The nonionic crosslinked chain may be a branched polymer having a nonionic branched chain. The gene transfer agent can condense a nucleic acid such as DNA in high density by advantage on the structure. Since the gene transfer agent has a plurality of cationic branched polymers which are crosslinked, the gene transfer agent includes nucleic acids such as DNA in wider network, compared with a gene transfer agent composed of one cationic branched polymer and exhibits excellent gene transfer activity.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a retroviral vector from which most of viral elements are removed, as the elements are not useful in integrated proviruses and may cause many problems, though the retroviral vector contains cis-acting viral elements for expression, encapsidation, reverse transcription and integration of retroviral genome nucleic acid sequence.  &lt;P&gt;SOLUTION: The vector uses the Cre-lox recombination system of bacteriophage P1. The loxP site comprising 32 nucleotides is inserted into the 3&#39; LTR U3 region with a gene to be inserted to the cell. After loxP is duplicated in the presence of the LTR, the LTR may be recombined with the enzyme Cre. The structure of the resulting provirus in the host genome corresponds to a single LTR containing a single copy of the gene to be inserted to the cell.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a multicolored cosmetic having good usability and a three-dimensional structure.  &lt;P&gt;SOLUTION: This cosmetic is the three-dimensional structure composed of a plurality of cosmetic composition groups. In the three-dimensional structure, the boundary among the plurality of cosmetic compositions composing the three-dimensional structure is definite and the plurality of cosmetic compositions are integrated. The cosmetic is produced by passing through the following steps. (Step 1) is a step of slowly adding an aqueous solution of gypsum while stirring the gypsum and powder, carrying out fluidized bed granulation and preparing a coarse grain of the cosmetic composition. (Step 2) is a step of arranging the shape of each grain. (Step 3) is a step of mixing the grain and/or coarse grain of each cosmetic composition. (Step 4) is a step of integrally molding the grains of respective cosmetic compositions each having the arranged shape.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a site marker including a generally hollow body defining a cavity.  &lt;P&gt;SOLUTION: The site marker is characterized by the followings. A deployment line within the site marker positions at least one marker element within the body portion. The deployment line has a first end that is fixedly secured to a first end of the body portion and a second end that is secured to a second end of the body portion. The deployment line is pre-biased so as to pull the first end of the body portion towards the second end of the body portion, and thereby expand the body portion.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a medicine for ameliorating anorexia so as to recover a patient in low nutritional state caused by chronic reduction in oral intake of nutrition resulting from serious anorexia not related to organic diseases such as digestive system diseases, etc., transient symptoms such as cold, fever, sleep deprivation, stress, etc., especially a patient of elderly person in a low nutritional state.  &lt;P&gt;SOLUTION: The medicine comprises essential oil of black pepper as an active ingredient. A person can get rid of nutrition supplement therapy by infusion solution, intubation/nutrition tube insertion by using essential oil of black pepper so as to ameliorate anorexia in a patient in a low nutritional state by a serious anorexia and to recover a lower nutrition state. The risk of senility syndrome by infection associated with low nutritional state, bedsore and fracture by fall, etc., is reduced. Consequently, burden of caregiver is reduced and a health care cost is controlled.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
NEW MATERIAL:4&#39;-Lower alkoxy-2-alkoxycarbonyldibenzoylmethane of formula I (R1 is 1-18C straight or branched alkyl; R2 is lower alkyl). EXAMPLE:4&#39;-Methoxy-2-methoxycarbonyldibenzoylmethane. USE:Useful as an ultraviolet-absorber for cosmetic such as skin cosmetic, hair cosmetic, etc. The compound of formula I is fat-soluble odorless crystal or oil having light yellow color, effective to absorb harmful UV-A region ultraviolet radiation and protecting the skin from the adverse effect of the radiation. It has high age-stability to light and heat and is soluble easily in a solvent for cosmetic. PREPARATION:The compound of formula I can be produced by reacting the compound of formula II with a halogenation reagent in an inert solvent and reacting the resultant compound of formula III with an alcohol in the presence of a base.
The present invention relates to a sugar reducing yoghurt, which belongs to the technical field of processing medical foods. The sugar reducing yoghurt is characterized in that the yoghurt contains the ingredient of broom cypresses which are sugar reducing medicinal plants; broom cypresses in the yoghurt are extraction juices of leaves and stalks of broom cypresses, broom cypress leaves or broom cypress stalks. Through the technical scheme of the present invention, the original mouth feel and the original flavor of yoghurt is maintained in yoghurt products, and the nutritive value of the yoghurt of the present invention is enhanced; meanwhile, the yoghurt has a fresh color. Broom cypresses as an ingredient are added to the present invention, the defects of the shortage of the content of vitamins and inorganic salt existing in milk are overcome, and the present invention is particularly suitable for infants who have only few vegetables and fruits. The product of the present invention has the advantages of simple preparing method, locally obtained broom cypress and whole plant, easily acquired medicinal material with low price, low manufacturing cost, obvious effect on the treatment of diabetes through reducing blood sugar, and no toxic and side effect. The present invention is suitable for most people&#39;s eating habits, has universal application for a long term and also has the function of health care; consequently, the sugar reducing yoghurt has a broad market prospect.
Preparation of a cosmetic treatment formulation for keratinous material, comprises percolation of a fluid at a pressure of &gt;=3 bars through a composition comprising a cosmetic compound in the form of solid or paste in the presence of a cationic hydrotrope i.e. phenyl/pyridine derivative (I), where the electroneutrality of (I) is assured by an anion or a mixture of anions. Preparation of a cosmetic treatment formulation for keratinous material, comprises percolation of a fluid at a pressure of &gt;=3 bars through a composition comprising a cosmetic compound in the form of solid or paste in the presence of a cationic hydrotrope i.e. phenyl/pyridine derivative of formula (I), where the electroneutrality of (I) is assured by an anion or a mixture of anions. X : CH or N+&gt;R6; R61-10C, preferably 1-6C alkyl; R1H, 1-10C, preferably 1-6C alkyl (when X is N+&gt;R6) or -(CH2)nN+&gt;R3R4R5 (when X is CH); R3-R51-10C alkyl; n : 0-12; R21-4C alkyl; and p : 0-1. Independent claims are included for: (1) a cosmetic treatment of keratinous materials comprising preparing the cosmetic treatment formulation and applying the formulation on keratinous materials; and (2) a packaging device of composition comprising a closed housing bounded by at least a wall at least partially permeable to water vapor under a pressure of &gt;=3 bars, where the composition comprises a cosmetic compound and (I). [Image].
&lt;P&gt;PROBLEM TO BE SOLVED: To provide rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof, in which fluorescence arises from the interaction of two or more residues of the proteins, and nucleic acids encoding the fluorescent proteins.  &lt;P&gt;SOLUTION: There are provided: mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species; and mutants of wild type Discosoma sp. &#34;red&#34; fluorescent protein. Also there are provided: proteins that are substantially similar to, or mutants of, the above specific proteins; the fluorescent proteins; the nucleic acids encoding the fluorescent proteins; transformed cells; and antibodies against the transformed cells. Also, there are provided kits for use in such different applications, that include the nucleic acid compositions.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:A viral multiplication inhibitor, containing neplanocin C an active constituent and effective against humam T cell leukemic virus considered as the same kind as AIDS causative virus or Epstein-Barr virus which is a causative virus of Burkitt&#39;s lymphoma or epipharyngeal cancer. CONSTITUTION:A multiplication inhibitor for human T cell leukemic virus (hereinafter abbreviated to HTLV) or Epstein-Barr virus (hereinafter abbreviated to EBV) containing neplanocin C as an active constituent. The neplanocin C as an antimicrobial agent against plant pathogenic molds and carcinostatic agent is effective as a multiplication inhibitor for HTLV or EBV. The dose thereof is 50-200mg/day, preferably about 100mg/day for adults. Generally, the agent may be prepared as an injection is 5-10ml concentration aseptically prepared in distilled water for injection and intravenously injected. The agent may be prepared as a tablet or suppository.
PURPOSE:To obtain the title gel by adding, in advance, ethanol or ethylene glycol to an aqueous solution of kefiran when the aqueous solution of kefiran is left at rest at low temperatures and gelled. CONSTITUTION:Kefiran obtained from kefir granules is made into a &gt;=1wt.% aqueous solution followed by adding ethanol or ethylene glycol to this solution, and the resultant solution is left at rest at low temperatures (pref. ca.5 deg.C). The amount of the ethanol or ethylene glycol to be added is ca.2-10vol.% (pref. 4-8vol.%) based on the aqueous solution of kefiran. If an aqueous solution of kefiran with concentration comparable to that obtained by the above-mentioned process is incorporated with ethanol or ethylene glycol and casein or a phosphate salt and the resultant solution is left at rest at low temperatures, a gel of higher mechanical strength than that of a gel from the above-mentioned process can be obtained. The amount of the casein to be added is equal to or less than that of the kefiran present in the aqueous solution, and the amount of the phosphate salt (e.g., Na salt) to be added is pref. ca.0.1-1M.
NEW MATERIAL:A fibrin-adsorbing urokinase complex composed of a polymeric urokinase and a plasmin wherein the heavy chain of the urokinase is bonded with the heavy chain of plasmin through an S-S bond. USE:A thrombolytic enzymatic agent. It acts selectively to the thrombus at a low dose, is metabolized and secreted slowly, hardly affected with plasmin inhibitor, and capable of continuing and exhibiting sufficiently high thrombolytic activity compared with the single use of urokinase. There is little side effects such as systemic hemorrhage. PREPARATION:The heavy chain of a polymeric urokinase is made to react with large excess of 5,5&#39;-dithio-bis(2-nitrobenzoic acid) to effect the addition of dithionitrobenzoate gtoup to the cystine residue participating in the bonding with the light chain with said heavy chain. The obtained heavy chain of a polymeric urokinase added with dithionitrobenzoate is made to react with a plasmin heavy chain to obtain the objective complex. The reaction is carried out at 0-40 deg.C in a buffer solution of 6-8pH.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an ophthalmologic composition enhanced in the effect of cooling a region to which it is applied and reduced in the initial stimulus when it is applied.  &lt;P&gt;SOLUTION: The ophthalmologic composition comprises (A) a monocyclic monoterpenoid and (B) a monoterpene alcohol in such amounts that 0.01 to 2,000 pts.wt. (B) is present per 1 pt.wt. (A). This composition is enhanced in the effect of cooling a region to which it is applied because the surface temperature of the region is lowered, and the cooling effect is sustained, and is reduced in the initial stimulus when it is applied, and is excellent in functionality.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI